RESISTANCE TO ANTIBIOTICS
THE UNMET NEED
Multidrug-resistant bacterial infections are a growing global pandemic.1
Without action, resistance to antibiotics will kill more people than cancer by 2050.1
A global public health crisis has emerged as we head towards a post-antibiotic era.
THE PIONEERING SOLUTION
Peptilogics is an early-stage biotechnology company. They are utilizing an innovative platform technology to develop a novel class of antibiotics based on cationic antimicrobial peptides. Their product has a unique and novel mechanism of action computationally engineered to kill all ESKAPE pathogens.
Peptilogics antibiotics function better than all available drugs, and bacteria do not become resistant to them – potentially halting the global ‘superbug’ pandemic.
The company has received QIDP status from FDA and is in its first in man Phase 1 trial.
1. The Review on Antimicrobial Resistance 2016 https://amr-review.org Accessed April 2018.